A SINGLE ARM, OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF VAL-1221 ON SUBJECTS WITH LAFORA DISEASE
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Cetirizine (Primary) ; Clervonafusp alfa (Primary) ; Paracetamol (Primary)
- Indications Lafora disease
- Focus Adverse reactions
Most Recent Events
- 06 Sep 2023 New trial record